Meeting
2023 ASCO Annual Meeting
Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update.
Authors
Senthil Damodaran
University of Texas MD Anderson Cancer Center, Houston, TX
Senthil Damodaran , Halle C. F. Moore , Ian Churchill Anderson , Mathew Amprayil Cherian , Ciara Catherine O'Sullivan , Paul V Plourde , David Jay Portman , Matthew P. Goetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT04432454
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1057)
DOI
10.1200/JCO.2023.41.16_suppl.1057
Abstract #
1057
Poster Bd #
278
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies.
First Author: Senthil Damodaran
Poster
2015 ASCO Annual Meeting
A phase Ib study of abemaciclib with therapies for metastatic breast cancer.
First Author: Sara M. Tolaney
Poster
2024 ASCO Breakthrough
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.
First Author: Joohyuk Sohn
Poster
2023 ASCO Annual Meeting
TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.
First Author: Rachel M. Layman